Editorial NO FOOT NO VETERINARIAN Brand of Po/ysulfated Glycosaminoglyoan (PSGAG) Solution 500 m9/5 mL For intramuscular ll.M.) use in horses DESCRIPTION Each 5 milliliters of Adequan ~ i.m contains 500 mg of Polysulfated Glycosaminoglycan and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonieity. PHARMACOLOGY Polysuffated Glycosaminoglycan is chemically similar to the mucopolysacchabdes of cartilaginous tissue. It is a potent proteolytic enzyme inhibitor and diminishes or reverses the processes which result in the loss of cartilaginous mucopolysaccharides. PSGAG improves joint function by stimulating synovial membrane activity, reducing synovial protein levels and increasmg synovial fluid viscosity in traumatized equine carpal joints TOXICITY Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the iniection site or in the affected joint No animal had any clinical illness during the trials and none showed clinical or taboratory evidence of toxicity. INDICATIONS Adequan ® i.m is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses CONTRAINDICATIONS There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan WARNING Not for use in horses intended for food DOSAGE AND ADMINISTRATION The recommended dose of Adequan ~ i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan ® i.m. with other drugs or solvents. REPRODUCTIVE SAFETY Studies have not been conducted to establish safety in breeding horses. CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian. WARNING Keep this and all medications out of the reach of children.
HOW SUPPLIED Adequan ~ i.m solution, 500 mg/5mL is available in 5 mL glass am,pules or vials, packaged in boxes of 4. STORAGE CONDITIONS Store in a cool place 8 ° - 15°C (46 ° unused poriion. ~ 1 ~
LUITPOLD PHARMACEUTICALS, INC. Animal Health Division Shirley, NY 11967 (516)924-4000 LUITPOLD 1-800-458-0163 Made in US,A, IN 99501 Rev.04/92 MG 8491 NADA #140-901, Approved by FDA
Dr. R. F. Redden, of Versailles, Kentucky, wrote to me recently, "Bill, the horse owners of the world are demanding a higher level of expertise in all fields and veterinarians that elect to deal with equine lameness must not only develop a thorough knowledge of the basics, but stay abreast of new concepts, techniques and marketed products." Back in 1987 Redden held a meeting in Lexington, Kentucky, on laminitis. Veterinarians and farriers flocked in from all over the United States (some from overseas) and there was standing room only. In fact, there was so much interest in the subject that Redden held another meeting on the same subject the following year, and eventually it became an annual affair. Last February the 8th Annual Bluegrass Laminitis Symposium was held. "We had a very successful meeting," Redden wrote, "700 plus in attendance with 15 countries represented. It was undoubtedly one of the most informative three days we have had over the past eight years. The veterinarians were certainly the minority this year with less than 50 attending." Nearly single-handedly Redden has raised the level of awareness about foot problems among equine practitioners. His annual symposia have broadened in subject matter, despite keeping the word "laminitis" in the meeting name. Out of the 19 lectures presented this year at the three-day meeting, only one was on laminitis, "Equine digital support system as a treatment for laminitis." The other material presented varied from "Clinical and pathological review of the coffin joint," to"Assessment and farriery treatment of mediolateral deformities in foals." A major goal in the annual symposia has been to bring veterinarian and farrier together in an effort to learn more from each other and in so doing, raise the standard for both professions. Redden has made a huge step in this direction, yet, he wrote, "1 find it difficult to understand how any equine veterinarian can practice sound medicine without the basics of this very vital field (equine podiatry). The farriers around the world are enthusiastically searching for a higher level of knowledge from basic balance to research and they are finding it very difficult in a lot of horse areas to find a foot-wise veterinarian to work with. Unfortunately, many do not take the foot seriously and fail to meet the farrier's level of expertise. The two professions must work with camaraderie and the efforts of their talents must be directed to a superb final product." William E. Jones, DVM, PhD
Journal of Equine Veterinary Science (ISSN No. 0737-0806) is published monthly (12 times a year) by William E. Jones, DVM, PhD, 20225 Grand Ave., Lake Elsinore, CA 92530-9998. Second class postage paid at Lake Elsinore, CA 92530. Postmaster: Send address changes to: Journalof EquineVeterinary Science, P.O. Box 1209, Wildomar, CA 92595.
Copyright © 1994 by William E. Jones. All rights reserved. No part of this publication may be reprinted or copied either wholly or in part without permission of the publisher. Subscriptions: P.O. Box 1209, Wildomar, CA 92595; phone (909) 6781889. U.S. subscription rate $60; Canada and Mexico $70; overseas and libraries $85. Payment must accompany order.